Category Archives: Pot Stocks

3 Marijuana Penny Stocks That Could Make You Rich

By investing in marijuana penny stocks now, you’re claiming your piece of what some are calling the new “gold rush.”

Legal marijuana sales in North America totaled $10 billion in 2017, and that’s expected to skyrocket 145% by 2021.

By now, everyone knows the dangers of investing in pot penny stocks. You should never invest what you can’t afford to lose.

But because the share price for one of these marijuana penny stocks is expected to climb over 300%, we had to make sure you saw this list today

Marijuana Penny Stocks to Watch, No. 3: Easton Pharmaceuticals Inc.

Easton Pharmaceuticals Inc. (OTCMKTS: EAPH) is known for making motion-sickness gel Nauseasol and anti-aging wrinkle cream Skin Renou HA.

Now it’s getting into the cannabis industry…

According to a 2017 report from Benzinga, Easton is part of a $1.3 million cannabis business deal with a Canada-based company, the Alliance Group. It’s already advanced the company $575,000. When the deal is final, Easton will receive a stake in 45 acres of a 135-acre parcel of land used for cannabis cultivation and production.

Until money is generated from the cannabis crops, Easton will receive 50% of Alliance’s revenue from its other businesses.

NINE LITTLE WORDS that could make you up to $1 million richer this election year. Click here…

It’s unclear if Easton will use the cannabis for its own business or just sell it to other pharmaceutical companies.

However, with Canada ready to completely legalize marijuana by Oct. 17, there should be increased demand from pharmaceutical and recreational companies to buy cannabis.

Over the last 52 weeks, the EAPH stock price has traded between $0.01 and $0.03 per share. Currently, the EAPH stock price trades at $0.01 per share.

The next marijuana stock on our list is creating a cannabis advertising solution for the $10 billion legal North American industry…

Marijuana Penny Stocks to Watch, No. 2: MCig Inc.

MCig Inc. (OTCMKTS: MCIG) is a full-service cannabis company that offers everything from greenhouse construction to production packaging.

And it’s now trying to capitalize on its reach throughout the marijuana industry with an online ad network…

On Oct. 10, 2017, the company announced the launch of its new cannabis online ad network, eHESIVE. Through the network, mCig will offer online publishers and advertisers a platform to target cannabis users.

This is a big deal for marijuana companies…

Cannabis companies can’t advertise on Facebook Inc. (Nasdaq: FB) or Google.

And because Facebook has over 2 billion monthly active users and over 77% of global Internet searches are made on Google, these marijuana businesses are left at a disadvantage when it comes to reaching new customers.

The eHESIVE platform solves this problem by allowing marijuana businesses to advertise on its platform and reach new customers. And the company is extremely optimistic about its profit potential.

“DoubleClick, an ad network that survived the dot-com crash, was acquired by Google for $3.1 billion. As mCig develops its market share early in the game, the company also expects its advertising segment to also reach a significant valuation,” a 2017 MarijuanaStocks.com report said.

Over the last 52 weeks, the mCig stock price has traded at a low of $0.12 per share and a high of $0.42 per share.

Today (Sept. 13), the mCig stock price opened at $0.26 per share.

But as the company grows eHESIVE, it should increase its revenue and attract more investors, potentially sending the stock price higher.

“EHESIVE is the enterprise digital marketing solution I wish we had when mCig entered the cannabis industry,” mCig CEO Paul Rosenberg said, according to MarijuanaStocks.com.

And while mCig is certainly a marijuana stock to watch, the stock price of this next company is expected to go absolutely vertical in the next 12 months.

One year from now, shareholders could be smiling at their 324% return…

Marijuana Penny Stocks to Watch, No. 1: 22nd Century Group Inc.

22nd Century Group Inc. (NYSEAmerican: XXII) is a plant-biotech company known for its ability to regulate the level of nicotine in plants with advanced engineering technology. XXII grows tobacco with up to 97% less nicotine than conventional tobacco, according to its website.

Smokers are looking for reduced-risk tobacco products, which has made the U.S. e-cigarette industry worth $2.9 billion in 2017.

And with the total U.S. tobacco market worth $120 billion in 2018, it’s a profitable industry.

But in addition to tobacco, 22nd Century is using its advanced tech in the cannabis market…

Currently, the presence of THC (a psychoactive constituent of cannabis) in crops is one of the biggest challenges for hemp farmers. Hemp crops containing above 0.3% THC are required by U.S. law to be destroyed.

22nd Century is currently developing industrial hemp plants that contain zero THC.

Through its subsidiary, Botanical Genetics LLC, XXII is also working on optimizing hemp for various climates around the world.

By 2025, the global hemp market is expected to generate $10.6 billion in sales, according to Grand View Research Inc.

Today the XXII stock price opened at $2.71 per share. In the next 12 months, global investment bank Chardan expects the XXII stock price to climb to $11.50 per share.

That’s a potential 324% gain in a year.

But that’s not the only profit opportunity in the cannabis market.

This election year, four cannabis stocks are potentially destined to soar up to 1,000%…

In the election year of 2012, marijuana stocks started rare gains of as much as 3,240%.

In 2014, they started producing up to 4,606% profits.

In 2016, they began rare climbs of 6,074% and more.

How much richer could select cannabis stocks make YOU in the election year of 2018?

It’s not silver or platinum. It’s not aluminum, nickel or lithium, either. But this “magic” METAL is found in everything from cars to airplanes, smartphones and computers, even batteries and cosmetics. It even has the power to fight diabetes, depression, weight loss and cancer. It’s worth billions, even trillions. But here’s the problem—this metal is disappearing. The world’s reserves are quickly being sucked dry. But a group of geologists have just struck the motherlode, and the one company behind it could earn investors an absolute fortune as they solve the greatest commodity crisis in human history. [FOR MORE INFORMATION CLICK HERE]

Source: Money Morning

9 Marijuana Stocks to Play the Pot Craze

Source: Shutterstock

Most of the time, most stocks move in the same direction as the broad market … a troubling reality given the market’s recent lack of traction.

There are occasional, story-driven exceptions to that rule of thumb though. Marijuana stocks, fueled by what may well be the biggest legal and medical revolution in years, have already proven they’re blazing their own trail. Stepping into the right pot stocks at the right time can translate to incredible gains, whether or not that outfit is profitable. (And, most aren’t.)

To that end, here’s a rundown of the market’s top pot stocks for the foreseeable future. They may each require different trading treatment. Some are long-term positions, while others are nothing more than hype-driven trades.

In all cases, though, there’s explosive potential on the table — the legal marijuana industry’s story has just gotten that compelling, as more states seek to legalize it while regulators finally start to see its legitimate medical benefits.

In no certain order…

Marijuana Stocks to Buy: Canopy Growth (CGC)

Source: Shutterstock

Marijuana Stocks to Buy: Canopy Growth (CGC)

Of all the marijuana stocks worth a look right now, Canopy Growth (NYSE:CGC) has garnered the most attention of late. Spirits and liquor giant Constellation Brands (NYSE:STZ) upped its stake in the company from 10% to 38%, lending a great deal of credibility to up-and-coming company. All told, Constellation committed almost another $4 billion to Canopy Growth.

The deal-making didn’t stop there though. Canada’s Centric Health announced just a few days later it had entered a multiyear supply and service agreement with Canopy Growth … a deal that makes Canopy a supplier of medical cannabis to the specialty pharmacy.

There’s a reason other outfits are choosing to work with, and invest in, Canopy.

Marijuana Stocks to Buy: Cara Therapeutics (CARA)

Source: Shutterstock

Marijuana Stocks to Buy: Cara Therapeutics (CARA)

At first glance Cara Therapeutics (NASDAQ:CARA) looks like any other pharmaceutical company. It’s got a pipeline largely based on a unique molecular science and serves up regular updates on its R&D.

A closer look at Cara’s pipeline though — and specifically, the science behind it — reveals it is indeed a cannabis play. The drug designated as CR701, in preclinical development, leverages the pain-fighting properties of cannabis as a way of combatting neuropathic pain. Ultimately it may serve as an alternative to highly addictive opioids as a means of treating pain, including chronic and post-operation pains.

It’s certainly not a “pure play.” Cara stock has got five drug trials underway, none of which are cannabis-based. An opioid alternative is a huge opportunity though.

Marijuana Stocks to Buy: GW Pharmaceuticals (GWPH)

Source: ©iStock.com/CapturedNuance

Marijuana Stocks to Buy: GW Pharmaceuticals (GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) is another traditional-looking biopharmaceutical developer. Though it’s also not a pure cannabis play, it’s certainly more focuses on the use of cannabis than Cara Therapeutics is.

GW Pharmaceuticals’ claim to fame is Epidiolex … an epilepsy treatment that was the first cannabidiol (CBD) based drug approved by the FDA for that indication. It could launch any day now.

It won’t be cheap. The annual cost of the treatment will run about $32,500 per year, pointing not just to the effectiveness of the Epidiolex, but also to the rarity of the kinds of epilepsy it’s approved to treat; it’s limited to those patients with Dravet Syndrome and Lennox-Gastaut Syndrome. Regardless, Cowen believes annual sales of the drug could exceed $1 billion by 2022.

The first one is always the hardest win. Now that the FDA has given the green light to its first cannabidiol therapy, other cannabis-based drugs in its pipeline have at least slightly-lower hurdle to clear.

Marijuana Stocks to Buy: Cannabis Sativa (CBDS)

Source: Shutterstock

Marijuana Stocks to Buy: Cannabis Sativa (CBDS)

Don’t let the OTC-listing fool you. Cannabis Sativa (OTCMKTS:CBDS) has a stronger foundation and faces a brighter future than many of its exchange-listed peers and rivals.

Cannabis Sativa, in simplest terms, sells a variety of hemp-based products. Its lineup includes several CBD and THC infused goods, sold through a variety of different venues. Presto Doctor, Wild Earth Naturals, White Rabbit and hi Dispensaries are just some of the names operating under the Cannabis Sativa umbrella.

That being said, don’t misread what Cannabis Sativa is. It’s still booking heavy losses, and would only qualify as a speculative-grade play. Its best shot at long-term viability is a sweeping change in North America’s views on, and laws restricting, the use of marijuana. That change may be underway, but it remains to be seen if it’s moving fast enough.

Marijuana Stocks to Buy: Tilray (TLRY)

Source: Shutterstock

Marijuana Stocks to Buy: Tilray (TLRY)

Tilray (NASDAQ:TLRY) is another one of the names that’s been in the spotlight of late, and for good reason. The company’s fiscal Q2 report posted last month — its first ever quarterly report as a publicly traded company — indicated revenues had nearly doubled year-over-year.

The company is still losing money, to be clear. In fact, the net loss grew from $2.4 million in the second quarter of last year to a loss of $12.8 million last quarter. Investors weren’t deterred though, knowing the company is a work-in-progress.

They’re not wrong to be optimistic about future growth. Tilray was recently chosen by Nova Scotia Liquor Corporation to be a supplier of the adult-use cannabis products it intends to begin selling next month, and just last week the company announced that Prince Edward Island Cannabis Management Corp. had also tapped Tilray for adult-use cannabis products. It’s quickly becoming a go-to supplier.

cbd medicine

Source: Shutterstock

Marijuana Stocks to Buy: Insys Therapeutics (INSY)

Insys Therapeutics (NASDAQ:INSY) is yet another pharmaceutical developer aiming to harness the medical benefits of marijuana.

It has already got two of them on the market. Sybsys is a sublingual spray approved for the treatment of pain in cancer patients, and Syndros is an oral solution that treats people suffering an HIV-related loss of appetites or the nausea and vomiting often resulting from anti-cancer medications. Several more are in the works.

Perhaps just as important is the fact that Insys is attracting its fair share of developmental partners too. The company announced a week ago that it would be expanding its collaboration with UC San Diego’s Center for Medicinal Cannabis Research to explore the use of cannabidiol as a treatment for psychosis.

Marijuana Stocks to Buy: 22nd Century Group (XXII)

Most investors familiar with 22nd Century Group (NYSEAMERICAN:XXII) know it as a smoking-cessation play … or at least an outfit that’s capable of growing less-dangerous tobacco.

That’s not all 22nd Century Group is, though. Investors who look closely will see that this company controls several patents related to cannabis plants, which in turn gives the company a hand in the cannabinoid business. Akin to its low-nicotine tobacco plant, it’s been working on the development of a no-THC cannabis plant.

It has not done a great deal with that technology yet. But, with years of work on low-nicotine tobacco about to bear fruit (mandates for low-nicotine tobacco are now being discussed) 22nd Century Group may soon be able to put more focus on its next big evolution.

Marijuana Stocks to Buy: ETFMG Alternative Harvest ETF (MJ)

Source: Shutterstock

Marijuana Stocks to Buy: ETFMG Alternative Harvest ETF (MJ)

Can’t decide which of these marijuana stocks to buy? You don’t have to. Own a piece of all of them via the ETFMG Alternative Harvest ETF (NYSEARCA:MJ). Four of its top five holdingsearned a spot on the list you’re reading right now, collectively comprising about one-third of the fund’s portfolio alone.

Where the ETFMG Alternative Harvest ETF really stands out, however, is its capacity to offer U.S. investors exposure to several Canadian cannabis stocks that may be difficult to purchase outside of that country.

It matters. Although the United States is increasingly open-minded and educated about the use marijuana, Canada has proven far more liberal and progressive. It’s easier for small start-ups to do well there. MJ allows non-Canadians an opportunity invest in that more fostered growth.

Marijuana Stocks to Buy: Cronos Group (CRON)

Source: Shutterstock

Marijuana Stocks to Buy: Cronos Group (CRON)

Last but not least, add Cronos Group (NASDAQ:CRON) to your list of marijuana stocks to mull.

Cronos is a little of everything. Not unlike the ETFMG Alternative Harvest ETF, Cronos Group owns a stake — in some cases a 100% stake — in a handful of cannabis-related organizations. Unlike the ETFMG Alternative Harvest ETF though, Cronos isn’t a mere passive holder. It’s also an incubator of sorts, and will leverage its properties to create new growth opportunities. Case in point: Last month the company inked deals that make it a supplier to several Canadian retail distributors of recreational cannabis. Shortly before that, Cura also tapped Cronos as a supplier.

The company has been on the receiving end of some tough criticisms of late, and is now being targeted by attorneys hoping to build a class-action investors lawsuit. Those claims are often non-starters though. While they may push and pull the stock in the short run, often times news-prompted tumbles turn into opportunities.

As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley.

Pay Your Bills for LIFE with These Dividend Stocks

Get your hands on my most comprehensive, step-by-step dividend plan yet. In just a few minutes, you will have a 36-month road map that could generate $4,804 (or more!) per month for life. It's the perfect supplement to Social Security and works even if the stock market tanks. Over 6,500 retirement investors have already followed the recommendations I've laid out.

Click here for complete details to start your plan today.

Source: Investor Place 

5 Marijuana Stocks to Watch

Source: Shutterstock

To be honest, I’m not entirely thrilled about investing in marijuana stocks at the moment. Movement toward legalization at the state level in the United States and at the national level in Canada has sent a number of pot stocks soaring. But not all marijuana stocks necessarily are going to be winners. The sector may not be an outright bubble — yet — but there’s certainly a case that rising marijuana-related optimism has lifted all boats, including several that have some leaks.

As is so often the case in “hot” sectors, investors need to focus on quality stocks and the best companies. These five marijuana stocks offer ownership in companies that at least have proven their ability to drive revenue growth and have a coherent, solid plan for future profits.

Valuations are generally high across the space, and these stocks are not immune to that trend. But all at least have a chance to grow into those valuations — and don’t have the questionable business models or tactics of some of the smaller operators that have sprung up over the past couple of years.

5 Marijuana Stocks to Watch: GW Pharmaceuticals (GWPH)

5 Marijuana Stocks to Watch: GW Pharmaceuticals (GWPH)

GW Pharmaceuticals (NASDAQ:GWPH) might not be considered a marijuana stock by some investors. Rather, GW really is a biopharmaceutical company whose lead product happens to be derived from cannabinoids — a compound found in the marijuana plant.

That said, GW is a real biopharmaceutical company with a very attractive pipeline. Initial products such as Epidiolex and Sativex are used to treat epilepsy and spasticity caused by multiple sclerosis. And the growing acceptance of medical — and even recreational — marijuana likely will help GWPH longer term.

More patients will be willing to try marijuana-derived drugs, particularly as GW expands its indications. In the U.S., marijuana’s inclusion as a “Schedule 1” recreational drug still creates regulatory hurdles for the company. And down the line, the headline risk of an acquisition by a company like Pfizer (NYSE:PFE) or Merck (NYSE:MRK) would seem to be lessened as marijuana’s reputation turns from “evil” to “helpful.”

GWPH remains a high-risk play, like most early stage drug companies. Profits remain negative, and will remain so for several years. But GW Pharmaceuticals also has real promise — and an intriguing pipeline.

5 Marijuana Stocks to Watch: Canopy Growth (CGC)

5 Marijuana Stocks to Watch: Canopy Growth (CGC)

Source: Shutterstock

Canopy Growth (NYSE:CGC) has changed the recreational marijuana sector. In May, it became the first marijuana pure-play to be listed on the New York Stock Exchange. Last week, a major deal gave the entire industry a new level of credibility. Constellation Brands (NYSE:STZ, NYSE:STZ.B) — owner of Corona and Modelo beer, Svedka vodka, and other wine & spirits brands — is investing some $4 billion into CGC for a 38% stake in the company.

CGC shares soared on the news and have kept gaining, reaching a new all-time high on Monday. The only concern at this point is valuation. Canopy obviously has a huge growth opportunity in front of it, as Dana Blankenhorn detailed last month. But valuation is simply huge: at a market cap around $8 billion, CGC is trading at something like 170x trailing-12-month revenue.

If Canopy turns out to be a dominant wholesaler and retailer of marijuana, the current price could be cheap. But CGC is not a stock for the faint of heart. Indeed, few marijuana stocks are.

5 Marijuana Stocks to Watch: Tilray (TLRY)

5 Marijuana Stocks to Watch: Tilray (TLRY)

Source: Shutterstock

Canadian producer Tilray (NASDAQ:TLRY) went public last month. Soon after the IPO, I wrote that TLRY stock looked overvalued — and that it probably didn’t matter.

Indeed, TLRY has continued to push higher after initially falling back. Citron Research — better known as a short-selling firm — helped stoke the rally last week. In the wake of the Constellation-Canopy deal, Citron cited a $45 price target for TLRY — still 25% above Monday’s close (and an all-time high).

Here, too, valuation is a concern. TLRY trades at over 100x sales. But I might actually like Tilray’s business model more than that of Canopy. The company already produces medicinal marijuana for customers in ten countries. According to its prospectus, it was the first company to export marijuana (legally) from North America. It has a pharmaceutical partnership with Novartis(NYSE:NVS), and is moving quickly and heavily into the recreational space.

Tilary has a solid “first mover advantage” and a huge opportunity. I’d still worry about the stock price and margins: this is an old-line manufacturer at the end of the day, not a high-flying tech stock. But for investors who see the Canadian market as a multi-billion-dollar opportunity, TLRY is one of the better plays.

5 Marijuana Stocks to Watch: Cronos (CRON)

5 Marijuana Stocks to Watch: Cronos (CRON)

Source: Shutterstock

Cronos Group (NASDAQ:CRON) is another manufacturer with a nosebleed valuation. CRON has a market cap over $1 billion — and generated around US$3 million in revenue in its second quarter.

Admittedly, that figure rose 430% year-over-year, so there is some reason for optimism here. Cronos’ smaller size could make it a takeover target down the line, with Canopy off the table for now and Tilray perhaps looking to go it alone. Molson Coors (NYSE:TAP) has been looking for a deal in the space, and recently set up a joint venture for cannabis-infused beverages. It could theoretically be a suitor as well.

From here, CRON looks stretched, even by the standards of the sector at the moment. But with huge growth and a perhaps lower profile than the leaders, the company does have time and potential to one of the best, if not the best, performers in the space.

5 Marijuana Stocks to Watch: Scotts Miracle-Gro (SMG)

5 Marijuana Stocks to Watch: Scotts Miracle-Gro (SMG)

Source: Shutterstock

Unlike seemingly every other stock even tangentially related to marijuana, Scotts Miracle-Gro(NYSE:SMG) has struggled in 2017. SMG shares are down 27% so far this year, and hit a nearly two-year low earlier this month before a recent bounce.

But SMG still represents an intriguing “picks and shovels” play for the marijuana gold rush. The company’s Hawthorne Gardening unit targets the cannabis industry, and is acquiring Sunshine Supply to accelerate its growth and scale. Unfortunately, performance hasn’t been great of late, leading Scotts Miracle-Gro CEO Jim Hagedorn to unleash an expletive-filled tirade on his company’s fiscal Q3 conference call.

That said, as Will Healy pointed out, the long-term opportunity remains intact. SMG isn’t exactly cheap — but it’s certainly cheaper, and at 18x forward EPS cheap enough for investors to have some patience. (A 2.7% dividend yield helps as well.) Growth investors likely will go for the headline manufacturing stocks, but value investors seeking a back door to marijuana growth should take a long look at SMG.

As of this writing, Vince Martin has no positions in any securities mentioned.

Source: Investor Place 

Big Weed Is About to Collide with Big Money for Even Bigger Profits

Editor’s Note: Michael pushed this out to his free Strategic Tech Investor readers last night. Now that they’ve had the chance to get ready, we want to make sure everyone has a chance to cash in here. To get Michael’s free tech and pot stock investing research for yourself each week, just click here. Here he is…

I knew legal cannabis began to step out of the shadows and onto the big stage when some of its largest and best-run firms started listing on major U.S. stock exchanges.

Two Canadian companies have done that so far – uplisting their OTC-traded stocks to one of the big American exchanges.

At the end of February, Cronos Group Inc. (Nasdaq: CRON) uplisted to the Nasdaq, while Canopy Growth Corp. (NYSE: CGC) debuted on the New York Stock Exchange on May 19.

Both of those were big news at the time.

And for a very good reason, as I’ll show you…

Legal Weed Is Hitting In the Big Leagues Now

Quite simply, these young, aggressive, and above all well-positioned firms are now on the same playing field as some of the top tech names in the world.

That hasn’t escaped the attention of Wall Street.

Drop Everything: Canada just became the first major economy to legalize marijuana nationwide, giving investors a once-in-a-lifetime chance to potentially make millions of dollars from Canadian marijuana companies. Learn more…

You see, fund managers who run $1 billion-plus portfolios are often hamstrung by strict limits on what they can own.

Often, for example, they can only hold stocks that are traded on major exchanges. In other words, fund managers and other big spenders who like these companies now have the green light to buy. We’re talking about pension funds, mutual funds, hedge funds, and more.

That’s a lot of potential buying pressure from institutional investors that should keep interest alive – and money rolling in.

But, for all that, we still haven’t seen a cannabis initial public offering (IPO) on one of the big U.S. exchanges.

Until now…

Pot’s Potential Makes This One of Few IPOs Worth Following

A British Columbia-based cannabis startup – one I’ve been watching for years now – just began marketing its upcoming Nasdaq IPO.

A “roadshow” unlike any other is in the offing.

That means its executives and marketing team have signed up their banking partners… and are hitting the road in order to show (and, of course, sell) its IPO to big-money investors.

It values its IPO at near $1.5 billion – and will make its debut on the Nasdaq Global Select Market exchange.

“In general, U.S. capital markets have generally been closed to growers. [This company] is reflecting that exchanges like Nasdaq and New York [Stock Exchange] are starting to open up to the fact that cannabis is a legitimate marketplace,” Scott Greiper, president and founder of cannabis-focused investment bank Viridian Capital Advisors, said. “Every exchange is looking to be on the front lines of capital markets.”

And that trend is only going to escalate as more U.S. states – and more nations around the world – continue to legalize cannabis.

This seed-to-sale cannabis company has a long history of being a “first mover” in its sector. Not only is it the first marijuana company to IPO on a major U.S. exchange, but it was the first Canadian cannabis company to distribute its marijuana at home and internationally.

That gives it entry into not only the $4.7 billion Canadian market, but the international market as well. That market is expected to reach $57 billion by 2027, according to Arcview Market Research – and some analysts believe it could reach $1 trillion in short order.

When this company makes its debut, it’ll complete the perfect “Big Weed” triple-play, along with Cronos and Canopy Growth – two pot stocks I recommend accumulating here.

Canada’s Cannabis Billions Could Be Unleashed, Potentially Overnight

Now, I’ve already laid out my case for this soon-to-be public Canadian company in a special report that’s free to select members of my Radical Technology Profitsservice. You can click here to learn how to get it.

I told those subscribers that it’s the “Canadian cannabis IPO I’m watching closest right now” – and that was before the Nasdaq news broke.

But the truth is, weed investing is about more – much more – than a promising IPO.

Just to give you an idea of the potential here, by 2027, it’s expected that about 40% of all legal marijuana across the globe will be sold in Canada. All told, Canada’s total legal weed market – when you add in the growers, the value-added product makers, the testing labs, security, tourism, exports, and all the rest – could soon reach $22.6 billion, according to Deloitte.

Those incredible statistics cannot be understated.

And they’re why I believe investors should be focusing their attention on Canada-based marijuana companies and stocks, like Cronos and Canopy Growth.

I can’t believe this “surfer dude” beat all those Wall Street legends... ​650 of the world’s biggest and brightest minds... I’m talking about legends like Mario Gabelli... David Einhorn... Joel Greenblatt... and Rick Rieder... who, combined, manage more than $5 trillion. All were forced to bow down to one “unheard of” trader from Laguna Beach. Click Here to discover the strategy he used while he had sand between his toes.

Source: Money Morning 

3 of the Best Marijuana Stocks to Buy in July 2018

We’ve been telling Money Morning readers that marijuana is one of the most explosive industries you can invest in this year.

Today, we’re going to show you three of the best marijuana stocks to buy in July 2018.

The 4 Cannabis Stocks to Buy Now – Profits of Up to 1,000% Could Be Likely This Election Year!

But first, we want to show you why it’s such an important moment for marijuana investing

Marijuana Sales Will Soar Through 2021

Marijuana is rapidly being legalized across the United States and Canada.

That’s leading to a flood of revenue coming to the companies successfully positioned to capitalize on the wave of legalization.

Sales of legal cannabis in North America are forecast to reach $24.5 billion by 2021, up from only $10 billion last year. In other words, in only four years marijuana sales throughout North America will jump a whopping 145%.

best marijuana stocks to buy

The sales will be driven by the growing legalization in the United States and Canada.

Canada will fully legalize cannabis this fall, after voting to approve it on June 7.

And more U.S. states may join Canada in 2018’s election cycle. New Jersey and Arizona are among the states contemplating legalization.

But even as states move to legalize cannabis, it’s still illegal under federal law. There were fears that U.S. Attorney General Jeff Sessions – a marijuana critic – would harshly enforce federal law against states that legalized cannabis.

Plus, marijuana being federally illegal keeps banks and financial services from providing cannabis companies with much-needed cash and security.

That’s keeping a lid on some marijuana stocks for now, but it’s not going to last…

U.S. President Donald Trump is already considering support of legislation that will protect the states that have legalized pot.

If the president does that, Sessions will have to follow suit, no matter how much he doesn’t like marijuana legalization.

And it’s simply a matter of time before federal law is brought into the 21st century, and marijuana is treated with a hands-off approach.

That means there’s still time to get in early on the best pot stocks before they truly soar.

But there are so many cannabis stocks listed, it’s tough for investors to find those worth owning. Some lists contain up to 227 different companies.

Instead, we’re making it easy…

Here’s our list of the three best marijuana stocks to buy…

The Best Marijuana Stocks to Buy in July 2018

To help narrow down the universe of marijuana stocks, we turned to marijuana expert Wil Ralston.

Wil is president of SinglePoint Inc. (OTCMKTS: SING), a holding company for cannabis and technology. The company focuses on small to midsize company acquisitions, specializing in emerging markets and mobile technologies.

We believe Ralston is in a great position to focus on the superior profit plays in the sector. And he’s pointing to two stocks we’ve been on top of at Money Morning.

These stocks are pick-and-shovel plays, just like the successful entrepreneurs who sold equipment to miners during the Gold Rush. Instead of hoping to hit it big with a gold mine, they instead raked in a fortune from everyone who tried.

We have two favorite pick-and-shovel stocks, and they are the same ones Ralston likes.

They are ScottsMiracle-Gro Co. (NYSE: SMG), which is on the agricultural side of legal cannabis, and Microsoft Corp. (Nasdaq: MSFT), which is on the financial side.

SMG is known to nearly every American lawn owner as the provider of lawn care products. But the company is pivoting to help marijuana growers too. SMG acquired a hydroponics company this year for $450 million. Hydroponics allows plants to grow in water inside greenhouse nurseries instead of fields and is one of the most popular ways to cultivate marijuana.

MSFT is also getting in on the action. Microsoft is partnering with KIND Financial, which offers legal compliance services to the marijuana trade. Marijuana companies have to be careful to comply with all laws, and that means using a digital network to archive and track their shipments and sales. KIND supplies that software thanks to Microsoft’s Azure cloud system.

As Ralston points out, venerable blue-chip firms like SMG and MSFT getting involved in the marijuana industry indicates the growing confidence they have in the future of the sector. Investors can not only profit from these companies – they can also feel heartened by the sign that the marijuana industry is beginning to standardize as legalization increases.

We also turned to another industry expert, Frank Lane. Frank is the president of CFN Media Group, a premier creative shop and media network working within the legal marijuana industry.

As we mentioned earlier, because of federal laws prohibiting marijuana sales, cannabis companies often struggle to find reliable banking partners.

But this isn’t a problem in Canada, and one company is focusing on helping finance new cannabis operations in our neighbors to the North.

Cronos Group Inc. (Nasdaq: CRON) is a marijuana investment firm based in Canada and listed on the Nasdaq. It was able to list in the United States because the firm is not in violation of any U.S. laws, which is a great opportunity for you.

Cronos Group specializes in investments in firms that are engaged in Canadian medical marijuana, firms that are either seeking a license or already licensed.

And with full marijuana legalization launching in Canada by September 2018, now is the best time to get in before the CRON stock price really takes off.

Cronos owns Peace Naturals Project Inc., a company that is licensed to sell medical marijuana and cannabis oil in Canada.

It also owns Original BC Ltd., another company licensed to sell medical marijuana in Canada.

When the cannabis boom takes off up north, Cronos is ready to profit.

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

Marijuana Stocks: Two to Consider, Two to Avoid

Marijuana Stocks: Two to Consider, Two to Avoid

Source: MarihuanayMedicina via Flickr

The marijuana legalization movement is picking up speed. There have been various wins here and there, such as in Colorado and Washington. Uruguay became the first nation in the Americas to permit recreational marijuana usage in 2014. It further legalized marijuana pharmacies in 2017.

However, until now, no major country had legalized consumption on a national level. Marijuana stocks were waiting for a bigger market to come online.

That’s happened now. Canada has opened up marijuana to public usage. Its Senate approved legislation earlier this week which removes the last obstacle to legalized pot. It’s expected that Canadians will be able to consume legal weed as early as October.

Not surprisingly, investors are rushing to get in on the ground floor of this vast new market. Here are some marijuana stocks that could deliver big gains, and others that come with significantly more risk.

Marijuana Stocks to Consider: Constellation Brands

You may know Constellation Brands (NYSE:STZ) as a leading beer and wine company. And that’s true. But Constellation has big plans for the marijuana space in the future. The opening move for that came with Constellation buying a 9.9% stake in Canopy Growth (NYSE:CGC) this past October.

This was an obvious and attractive way to get exposure to the marijuana equity space at an attractive price. Canopy stock was at around $10 back then and is now at around $34.

And there is a bigger strategic plan at work as well. Constellation wants to sell marijuana-infused products itself. The company has said that it’s too early to tell whether marijuana legislation will help, hurt or be neutral for alcohol companies. As a result, it is hedging its bets by selling pot-infused beverages of its own. As the company put it earlier this year:

“Our goal with this organization [Canopy] is to work collaboratively to both understand the cannabis business but also develop unique cannabis-based beverages that will be available around the world as legalities prove those to be an option.”

A Canopy spokesperson suggested that marijuana-infused products, such as beverages, won’t be legal in Canada until next year. However, she went on to add: “That said, we are already preparing for the opportunity to brand and market these products, once federal regulations permit.”

In the meantime, Constellation has its leading portfolio of beer and wines, including brands such as Corona. With STZ stock at 21x forward earnings, this is a reasonable way to get a shot at the marijuana market without taking massive downside risk.

Marijuana Stocks to Avoid: Canopy Growth

Let’s turn from Canopy’s 10% stock owner, Constellation Brands, to Canopy itself. Unfortunately for average investors, Constellation got in at a way better price than we could now.

Last fall, Constellation paid C$245 million (US$184 million) for 9.9% of Canopy Growth. CGC stock is now selling with a market cap of greater than $5.7 billion. That values Constellation’s share at $570 million, or triple their investment in under a year.

As stated above, that was a savvy move on Constellation’s part. But the price of CGC stock today bakes in some outlandish optimism. CGC stock now sells at more than 100x sales. The company sold only $55 million in product last year, but the market values that at more than $5.7 billion.

A 100x price/sales ratio is nearly unheard of in the history of publicly traded stocks. The general rule is to avoid stocks trading above 10x price/sales — maybe, just maybe you can get away with paying 20x for something growing at an incredible rate. But 100x sales is a bridge too far.

Sure, going forward, Canopy will be able to grow its revenues much more quickly. But a flood of competition will hit markets, lowering margins as well. And it’s not like Canopy was earning huge profits on its minimal revenue stream either. CGC stock is a story-driven mania at this point.

Once people double-check the math, they’ll see that Canopy won’t be able to create $5.7 billion in value anytime soon. A holding stake via a company like Constellation is a much safer way to invest, since it is a diversified business, and plans to roll out its own marijuana-infused products. And you don’t have to pay an arm and a leg for STZ stock like you do with Canopy.

Marijuana Stocks to Consider: Alcanna

Alcanna (OTCMKTS:LQSIF) is another marijuana stock worth considering today. Alcanna was formerly known as Liquor Stores N.A. Ltd. and ran, not surprisingly, liquor stores in Canada and the United States. It has realigned its business model in recent months, however. It’s divesting some of the U.S.-based liquor stores to become a more Canada-focused operation.

And, most importantly, Alcanna will now become a marijuana retailer. Alcanna currently operates about 175 liquor stores in Alberta, along with a smaller number in British Columbia. That gives it a nice position in the sales of already heavily regulated goods. That makes it a natural player for building out a marijuana retail business.

The company also earned a sizable endorsement. Aurora Cannabis (OTCMKTS:ACBFF) bought 25% of Alcanna earlier this year for a more than $100-million investment. That gives Alcanna plenty of capital to build out its retail business and a close partnership with one of Canada’s big emerging producers.

There is plenty of risk here. Alcanna had a mixed track record as a pure-play liquor store operator. Adding marijuana to the mix doesn’t guarantee success. But the valuation is reasonable, and Alcanna offers an interesting 4% dividend yield while waiting for the growth story to potentially play out.

Marijuana Stocks to Avoid: Neptune Technologies

Neptune Technologies (NASDAQ:NEPT) is a long-running story stock. Almost a decade ago, the company hyped up its krill oil, extracted from a type of small Arctic crustacean.

Neptune positioned krill oil as a superior alternative to fish oil, which companies such as Amarin(NASDAQ:AMRN) sell. Amarin obtained FDA approval for Vascepa, its fish oil-based pharmaceutical drug, for cardiovascular benefits.

Neptune, by contrast, never achieved similar success. While NEPT stock gyrated widely, krill oil never took off. A fatal factory explosion in 2012 set the company back farther. Last year, Neptune finally threw in the towel on krill oil, selling off its manufacturing business for $34 million. NEPT stock slumped to multiyear lows below $1/share following the news.

However, Neptune wasn’t done. It decided to pivot, not surprisingly, to marijuana. Instead of getting an extract from tiny marine life, the new plan is to extract oil from cannabis. It also has suggested that it may combine cannabis with omega-3 oils, though it’s unclear what potential synergies the two would have in combination.

And NEPT stock flew earlier this week following news that it will partner with Canopy Growth to make marijuana extracts in a multiyear deal. The press release provided little in the way of tangible details. Regardless, it was enough to shoot NEPT stock up to $4, giving it a $350-million market cap.

Could Neptune’s cannabis extracts become a big market? Sure. Is it worth a $350-million market cap for a company with a checkered past and no clear pathway to profitability in the future? Probably not.

  [FREE REPORT] Options Income Blueprint: 3 Proven Strategies to Earn More Cash Today Discover how to grab $577 to $2,175 every 7 days even if you have a small brokerage account or little experience... And it's as simple as using these 3 proven trading strategies for earning extra cash. They’re revealed in my new ebook, Options Income Blueprint: 3 Proven Strategies to Earn Extra Cash Today. You can get it right now absolutely FREE. Click here right now for your free copy and to start pulling in up to $2,175 in extra income every week.

Source: Investor Place 

This Pot Stock Has Uplisted and Is Poised for Massive Profit Potential

As I’ve mentioned numerous times by now, Canada is right at the doorstep of becoming the first G7 nation where the use of recreational cannabis is legalized for the entire country.

I can’t emphasize enough how big this is.

In fact, the recreational marijuana market in Canada could be valued at anywhere between $5 billion and $10 billion per year.

The company that I’ll be talking about today is one that I first recommended to myNova-X Report readers way back in 2016.

The company has recently gone through some exciting developments and can take advantage of the massive potential of the marijuana market.

You see, on May 24, the company uplisted, and its shares are currently trading on the New York Stock Exchange, in addition to trading on the Toronto Stock Exchange.

Here’s why this move will maximize this stock’s profit potential.

You see, uplisting will benefit the stock’s price, liquidity, and potential appreciation.

First, by moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base.

Second, the exchanges and market participants are more likely to offer greater liquidity and price discovery and be more active in supporting and trading the stock.

So let’s take a look at this Canadian pot stock and its potential for massive gains…

Canada’s Biggest Grower… Keeps On Growing

Canopy Growth Corp. (NYSE: CGC) is the biggest cannabis grower in Canada and has been expanding its capacity.

In fact, it’s poised to be one of the major global players in the industry as marijuana legalization spreads to more countries.

In addition to exposure in the blossoming Canadian market, Canopy already has agreements to export products to Germany, Australia, Spain, Denmark, Jamaica, Chile, and Brazil.

RELATED: Top five tiny Canadian pot stocks are set to skyrocket. Click here…

What’s more, one of Canopy’s investors is alcoholic giant Constellation Brands Inc. (NYSE: STZ), with a 9.9% stake in the company. That stake is worth a cool $191 million, and Constellation will have the option of purchasing additional stakes in the future.

It’s no coincidence that Constellation, which has a strong presence in California, made its move just months ahead of the state’s full legalization of marijuana.

Over the past year, Canopy has put more emphasis on its cannabis-oils products, as well, citing the higher profit margins of oils in its September quarter earnings report. Sales from oils increased 107% year over year, and the segment’s contribution to overall revenue rose from 14% to 18%.

The Brightfield Group estimates the global marijuana market will reach $31.4 billion by 2021. Should Canopy get 5% of the global cannabis market, it will grow sales by 250%.

Now, let’s take a look at what the stock currently looks like.

Two Exchanges, Plenty of Gains

Canopy is looking strong by closing above its initial New York Stock Exchange listing high once more. Though the cannabis sector isn’t yet fully on the same page, it can be comforted by the fact that Canopy, as its undisputed sector leader, continues to attract investors.

Shares of Canopy’s WEED on the Toronto Stock Exchange gapped up to $40 per share before retreating 15.76% over the next two-plus sessions as profit takers gained control.

Today is the second time Canopy Growth has breached $40 per share on a closing basis. On June 6, which was the day before Canada’s historic Bill C-45 vote was scheduled to take place, WEED finished at $40.68 per share after investors ran up prices in the sector in anticipation of a successful third reading vote.

Having accomplished that, the sector sold off around 8% over the next four days as a main underlying catalyst had been vanquished from the market.

Now that Canopy Growth has round tripped from sub-$34 and back – closing up $1.26 to $40.65 per share – investors have gotten past most of their recent post-legalization sell-off fears.

In fact, WEED closed just $0.03 shy of establishing a new post-NYSE closing high, meaning it can essentially set its sights on $41.40 and $44, which are the post-NYSE intraday high and all-time high, respectively.

Canopy’s seemingly uncontrollable appetite shouldn’t surprise anyone who is following the company. Last week, the company raised $500 million Canadian via convertible note offering, which was the largest ever in the cannabis space. The offering was upsized 25% from the previously $400 million Canadian aggregate principal amount announced just two days prior.

Endless Profit Opportunity for Just About Anyone

If you want to make a profit on the booming cannabis sector, then I suggest jumping onboard Canopy, where the opportunities and gains are seemingly endless.

But that’s just scratching the surface.

For instance, my paid-up Nova-X Report subscribers get total access to my Roadmap to Marijuana Millions model portfolio and stock research, which includes a full briefing on no less than five small caps, each trading for around $5, that are poised to explode when, as expected, Canada passes legalization. This is the kind of potential than can turn a tiny stake into $100,000 or more.

When Canada Takes Weed Fully Legal…

It’ll probably make our retrograde attorney general hopping mad, but there’s really nothing on Earth he can do to stop these small cannabis companies from hitting the stratosphere. Sessions could be furious, but folks who park a few hundred dollars into these “north of the border” firms could potentially turn a small stake into $100,000 – and fast.

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

The 3 Best Marijuana Stocks to Buy Today

Legal marijuana revenue is expected to soar 145% by 2021, jumping from $10 billion last year to $24.5 billion. Investors who act quickly can still get in early on this industry’s stunning growth potential with our top three marijuana stocks to buy today.

The $10 billion that the legal cannabis industry generated in 2017 is just the tip of the iceberg.

One prediction puts legal sales at $75 billion by 2030.

Marijuana stocks to buy today

When it comes to this industry, it’s essential investors do their homework to find only the best marijuana stocks. Many pot stocks can be risky investments and undergo volatile price swings. Plus, some upstart companies deal directly with the production and distribution of marijuana, which subjects them to regulation risks.

But the top pot stocks we’re bringing you today avoid many of these risks.

Each pot stock we’ll show you trades on a major exchange, has a diversified revenue stream that protects it from the ups and downs of a new industry, and is going to be an essential player in the marijuana industry as it grows.

That’s why we’re giving you our picks for several top “backdoor” pot stocks to watch

Best Marijuana Stocks to Buy Today, No. 3: Scott Miracle-Gro Co.

Scotts Miracle-Gro Co. (NYSE: SMG) has been on our list of top cannabis stocks to watch since 2016.

While you’re first thought about Scotts Miracle-Gro might not be marijuana, this is one of several cannabis “pick-and-shovel” plays that Money Morning recommends. Like the enterprising businesses who sold shovels to miners during the gold rush, this company profits from the marijuana industry without being directly involved.

Pot Stock Profits: A historic event is unfolding in California’s marijuana markets, and the wealth expected to flow into this industry is record-breaking. Learn how to cash in here…

This 150-year-old company is known for brands such as Evergreen, Roundup, Ortho, and Miracle-Gro. It has more than 8,000 employees and billions in annual revenue. This alone makes it attractive, but CEO Jim Hagedorn wants more.

In 2015, Hagedorn decided to expand the company’s reach into the booming legal-marijuana cultivation market. That year, SMG purchased two companies that specialize in fertilizer and soil for growing marijuana. The following year, it picked up a 75% stake in the hydroponics equipment company Gavita International.

Hydroponics allows a cultivator to grow plants without soil by using a water solvent that is treated with nutrient-rich solutions. This has become a popular method for growing marijuana, particularly where populations are dense.

Bloomberg reports that the hydroponics industry had generated approximately $250 million in annual revenue in 2016, and significant growth is expected in the future.

The company has continued to acquire other brands related to cannabis cultivation and hydroponics. These include Botanicare, Vermicrop, Agrolux, Can-Filters, and General Hydroponics. In April 2018, SMG announced plans to acquire hydroponics supplier Sunlight Supply for $450 million.

SMG stock currently trades for $81.26 and pays a generous 2.54% dividend yield. But the stock price is going to grow even more.

Company CFO Randy Coleman indicates that company sales could increase about 15% in 2018. The high, 12-month price target for SMG stock is $113, which represents 38.72% gains for today’s investor.

But the next company is adapting technology to the booming pot industry…

Best Marijuana Stocks to Buy Today, No. 2: Microsoft Corp.

Microsoft Corp. (Nasdaq: MSFT) is an unlikely pot stock to buy, but one of the best plays you can make.

MSFT is a blue-chip tech giant currently running the world’s second-largest cloud computing network with its Azure service. That cloud network is going to be essential to the legal cannabis industry.

Microsoft became an early tech player in the legal marijuana market through its cloud business with a lucrative partnership called Kind. Started in 2016, this is a software service that tracks cannabis from seed to sale.

Because the legal marijuana industry in most countries and U.S. states is so highly regulated, there must be tight controls in place that allow cultivators, dispensers, and regulators to track every cannabis plant, to ensure that players are 100% compliant with the laws. These controls also keep legal marijuana off of the black market.

As more states and countries pass laws to legitimize this industry, the need for these controls will continue to grow.

When you buy MSFT stock, you get the benefit of indirectly investing in legal marijuana, as well as the rest of Microsoft’s lucrative business.

Shares of MSFT are currently trading at $96.04, and the high price target for the stock is $130, which would deliver 35.36% gains over the next year.

And our top pot stock to buy right now is one you might not have heard of, but it could be the most profitable to own of all…

Best Marijuana Stocks to Buy Today, No. 1: Cronos Group Inc.

Cronos Group Inc. (Nasdaq: CRON) is one of the best pot stocks to watch right now.

And while it’s still a pick and shovel play, it’s more directly involved in the cannabis industry than Microsoft or Scotts Miracle-Gro.

Cronos is a Canadian investment company that invests in firms that are either growing or dispensing legal cannabis in Canada.

The company was the first cannabis company to achieve a Nasdaq listing, because it is not breaking any U.S. laws. It simply invests in marijuana companies without actually producing any marijuana itself.

Cronos owns Peace Naturals, which is a company authorized to sell cannabis oil and marijuana in Canada. It also owns Original BC, which is likewise licensed to distribute legal cannabis in Canada.

Marijuana is scheduled to become legal nationwide in Canada by September 2018, which means that now is the best time to invest in Canadian pot stocks.

The company also hopes to distribute worldwide and currently has an exclusive agreement with over 12,000 pharmacies in Germany. It is also participating in a joint venture to supply medical cannabis to Southeast Asia, Australia, and New Zealand.

Cronos had its IPO on Feb. 27, and shares are currently trading at $5.90.

And Canada’s upcoming marijuana legalization this summer could be one of the best profit opportunities you’ll ever see…

Get up to 14 dividend paychecks per month from safe, reliable stocks with The Monthly Dividend Paycheck Calendar, an easy-to-use system that shows you which dividend stocks to pick, when to buy them, when you get paid your dividends, and how much.  All you have to do is buy the stocks you like and tell them where to send your dividend payments. For more information Click Here.


Source: Money Morning

This Controversial Industry Is Here to Stay

It’s hard to tell when a stock is at the end of a strong run, or if the broader market is running out of steam.

But one thing to look for is how stocks react to bad news.

The more sensitive the stocks are to the bad news, the closer we are to the end of a recent rally and possibly going into a bear market.

On the other hand, if negative news has little effect, then the stocks still have room to run higher.

One particular group of stocks went through this just the other week.

There was an announcement that had the potential to put companies out of business, yet, despite an initial negative reaction in the stocks, shares have rebounded and held steady.

This is one industry that I honestly haven’t followed that much yet, as it is somewhat out of my wheelhouse. But the way the group as a whole reacted to the news recently has convinced me it is here to stay, and if you don’t have exposure to it yet — now is the time.

Marijuana Stocks: A Movement

The industry is marijuana stocks.

And I know, a lot of people have avoided these stocks because, well, let’s face it — it’s a drug that is illegal in most states.

That’s the same reason I haven’t followed it much. I’m not really a fan of the movement.

But after I saw how marijuana stocks reacted, it has me convinced the movement is here to stay, and apparently, more people in general are jumping on the bandwagon.

Now that the majority of people seem to be in favor of legalizing marijuana, aka cannabis, the movement may be here to stay.

That’s why a recent announcement that shook the industry was so important — I wanted to see how the stocks reacted.

U.S. Attorney General Jeff Sessions announced plans to roll back federal policies that paved the way for states to legalize marijuana — the policies that have allowed marijuana stocks to flourish and raised expectations for recreational marijuana to be allowed in more states.

This is when publicly traded marijuana stocks tanked on the news. Some were down more than 30% because, like I mentioned, a ruling like this is potentially sending many of these stocks into bankruptcy.

I was watching it as the news developed, and I bought my first marijuana stock on the dip. The buzz around the office was that the movement wasn’t going to end — and many investors feel the same way.

If you haven’t dipped your toes into this speculative trade yet, there’s still time. I have two stocks for you today that will reap the benefits as the movement stays intact.

Speculating on Marijuana

I’ll precede these two stock picks as speculative plays. Speculative because, indeed, a change in jurisdiction in the U.S. could put many marijuana-related companies out of business, and the two below would not be immune to such a change.

Plus, they each depend on further advancements in the recreational marijuana movement, which may or may not happen. So invest with caution, but it is an industry that needs to be on everyone’s radar at this point.

The first is the largest U.S.-traded pure marijuana stock — Canopy Growth Corp. (OTC: TWMJF).

Yes, both of the stocks I mention today trade on the pink sheets, or over the counter. These are stocks that typically have low volume and are risky bets. But with marijuana stocks, it’s where they are all listed and still have plenty of volume.

Canopy Growth is actually a Canadian stock that’s listed in the U.S. on the pink sheets but has an average daily volume of more than 1 million shares. The company has the highest individual market share in Canada’s medical marijuana market and will be poised to benefit a lot if Canada approves recreational marijuana use, which is expected to be passed in the coming months.

The other is Cannabis Science Inc. (OTC: CBIS). This company sells marijuana-based pharmaceutical and recreational products. It is opening two licensed dispensaries in Los Angeles this month and plans to open one more this quarter.

If you want exposure to a possible booming U.S. recreational market, this is the stock to own. It is traded on the pink sheets, but it has an average daily volume of nearly 30 million shares, so there is plenty of liquidity. However, it is a “penny stock,” trading at just $0.10 at last glance.

Again, these are speculative trades in an industry that is not quite established yet. But considering the way these stocks have held up despite major negative news, they’re stocks you should have on your radar.

Regards,

Chad Shoop, CMT

Editor, Automatic Profits Alert

In this exciting NEW VIDEO, Wall Street legend and former multibillion hedge fund manager Paul Mampilly pulls back the curtain on the biggest investment opportunity in the market today. What insiders are calling “The Greatest Innovation in History,” this revolution will mint more millionaires and billions than any technology that came before it. Right now, the current market for this technology is just $235 billion, but given how fast this technology is moving experts predict it will soar to $19 trillion by 2020. But 8,000% growth is just the beginning—and now’s your chance to get in on the action. [CONTINUE TO VIDEO]

Source: Banyan Hill 

2 Ways to Trade the Marijuana Industry

Marijuana was once completely legal in the United States.

No, honestly, it was before the 1900s.

The plant was used in most of our medicine. The Jamestown colony actually required its citizens to grow hemp. The police could arrest you for not growing it. Marijuana was even George Washington’s primary crop.

Then people began smoking it. Fearing violence and corruption, the government outlawed it.

Now, over 100 years later, states are legalizing marijuana again so that it is regulated and taxed like tobacco and alcohol. And it’s being legalized not just for medicine, but for recreational use as well. Savvy investors now have a new, highly anticipated market.

Marijuana is being legalized not just for medicine, but for recreational use as well. Savvy investors now have a new, highly anticipated market.

North Americans spent an estimated $53.3 billion on marijuana in 2016. However, about $46 billion of those sales were illegal. As more states continue to legalize marijuana, the legal sales will continue to snag market share. In 2016 alone, nine states declared marijuana legal, four of which for recreational use.

Right now, only nine states allow recreational marijuana use. That means the numbers in the chart above could be vastly underestimated.

As it becomes legal in more places, we will see sales surpass what they would have been if it were illegal.

Whether you agree with marijuana’s legalization or not, it is a growing market with ample opportunity to make some amazing profits. This industry could see expansion as more people use it due to its legal status and fading stigma. The open market will also work to lower the price.

Although there are not a lot of publicly traded marijuana companies, there are opportunities to invest in medical marijuana companies such as GW Pharmaceuticals (Nasdaq: GWPH), and growing companies such as Canopy Growth Corp. (OTC: TWMJF).

As it becomes legal in more places like alcohol and tobacco, there will surely be more investment opportunities ahead for traders to make some impressive profits.

Regards,

Ian Dyer
Internal Analyst, Banyan Hill Publishing

Right now, an untapped ocean of energy—found underneath all 50 states—is about to transform the world’s energy industry. In fact, there’s enough of this energy in the first six miles of the earth’s crust to power the United States for the next 30,000 years. Wanna know this untapped energy source? Learn NOW! And as companies rush to extract this energy from the ground, they’ll need the help of one Midwestern company’s technology to make use of it. This is your chance to take advantage of John D. Rockefeller-type fortunes. Early Bird Gets The Worm...

Source: Banyan Hill